FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Metastatic Cancer
Update : FDA approves new imaging drug for detecting spread of prostate cancer
Most relevant for: Men with prostate cancer
On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)
THIS INFORMATION HAS BEEN UPDATED on 5/10/2022: On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with metastatic triple-negative breast cancer
The ASCENT study confirmed an earlier study and showed that the drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)
Read MoreRelevance: Medium-Low
Strength of Science: Medium-High
Research Timeline: Animal Studies
Study : The buzz about honeybee venom: Promising early research to treat breast cancer
Relevance: Medium-Low
Strength of Science: Medium-High
Research Timeline: Animal Studies
Most relevant for: People with breast cancer particularly those with HER2-positive or triple-negative breast cancer.
Early research showed that melittin, an ingredient in honeybee venom, may be used to treat HER2-positive and triple-negative breast cancers. This study found that melittin can kill cancer cells. The chemotherapy drug docetaxel more effectively killed breast cancer cells in mice when combined with melittin. It is not known whether melittin would be safe or affect cancer growth in people. While promising, more research must be done before melittin could be used to treat people. (11/10/20)
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Inherited gene mutations found in pancreatic cancer families in Spain
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with pancreatic cancer and a family history of pancreatic or other cancers
This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : New imaging technology shows promise in detecting of spread of prostate cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Men with high-risk prostate cancer
A new imaging technique is currently being tested to see if it can detect the spread of prostate cancer sooner than standard imaging. Two clinical trials show that the new technique can detect the spread of prostate cancer in men who are newly diagnosed and in men whose cancer returns after treatment. (10/16/20)
Read MoreGuideline : FDA issues alert on a drug combination to treat triple-negative breast cancer
Most relevant for: People with metastatic triple-negative breast cancer
The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)
Read MoreStudy : Among women with breast cancer, who should have genetic testing for an inherited mutation?
Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer
Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
Read MoreUpdate : PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes
The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)
Read MoreUpdate : FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer
Most relevant for: Patients with Her2-positive metastatic breast cancer
The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)
Read More